As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the triple-G drug retatrutide, has met the primary endpoint for weight loss in another pivotal study. Though the results show competitive efficacy and tolerability, they may leave some observers slightly underwhelmed based on high expectations.